Back

Supernormal cardiac function: exercise vs. dapagliflozin

17 May 2025 (08:00 - 12:45)
Organised by: Logo
Congress Presentation Part of: ePosters in pharmacology and pharmacotherapy Antidiabetic Pharmacotherapy HFA Premium Access Heart Failure 2025 Heart Failure Association (HFA)

About the speaker

Photo
Miss Rebeka Rita Vago

University of Debrecen, Debrecen (Hungary)

4 More presentations in this session

Presentation thumbnail
Individual natriuretic and diuretic response in acute heart failure: insights from the PUSH-AHF pharmacological substudy
Doctor I. Beldhuis (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Real-world SGLT2i prescribing in an elderly population; a tertiary centre review
Doctor G. O Dea (Limerick, IE)
Abstract Slides Video
Presentation thumbnail
Association between congestion and aspirin resistance in patients with chronic coronary syndrome
Doctor I. Meray (Tyre, LB)
Abstract Slides Video
Presentation thumbnail
The PCSK9 targeted therapy - the best strategy to prevent cardiovascular complications in very high-risk patients in poland. Real-life data from the national health found B101 reimbursement program
Professor M. Banach (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
ePosters in pharmacology and pharmacotherapy

The Event

Event poster

Heart Failure 2025

17 May - 20 May 2025
You may be interested in
thumbnail
Congress Presentation
Impact of dapagliflozin on exercise-induced hypertrophy: insights from a rodent model of athlete's heart
thumbnail
Congress Presentation
Dapagliflozin effect on cardiopulmonary function, reverse cardiac remodelling and biomarkers in a cohort of HFrEF patients
thumbnail
Congress Presentation
Effects of SGLT-2 inhibitors on myocardial work in patients with heart failure with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources